Export‑Linked Pain: Pharmaceuticals – Biocon (***** • News factor (Karan): Elevated U.S. tariffs of 25% on Indian exports could hit pharma earnings significantly. • Key takeaway:

and peers (Sun Pharma, Dr. Reddy’s) could face a potential 2–17% EPS drag. • Beginner tip: Export-heavy pharma names may carry short‑term risk until tariff negotiations stabilize.